Purpose: Case Report: A 17-year-old male presented to the ED with midepigastric pain and recurrent vomiting. He has had multiple prior episodes presenting similarly, occurring 1-2 times per month for the last 6 years. He and his family have a history of migraines, and asthma. He takes ondansetron 4m g and sumatriptan 5 mg as needed. He admits to occasional alcohol and marijuana use. Review of systems is negative except for nausea, repeated episodes of vomiting, and moderate midepigastric pain, present only when he is vomiting. His last bowel movement was one day prior to presentation, and he has had no diarrhea or hematochezia. Physical exam revealed a healthy appearing young male actively vomiting, with midepigastric tenderness and an otherwise nonacute abdomen. Laboratory work up was unremarkable except for bicarbonate of 18, AST 125, and ALT 98. KUB showed normal bowel gas pattern with no evidence of obstruction or ileus. Discussion: CVS is a functional disorder that consists of recurrent paroxysms of nausea and vomiting separated by symptom free periods, with an average of 12 episodes per year. Onset generally occurs before the age of 5. CVS is an under recognized disorder that has no laboratory, radiographic, or endoscopic markers. Acute management focuses on attempting to abort the attack and decrease symptoms while preventing the complications of prolonged vomiting. Sumatriptan can be beneficial initially. Intravenous fluid containing glucose, which limits ketosis, can be effective in terminating attacks. Intravenous ondansetron has been shown to decrease the duration of episodes by more than 50%. Standard antiemetic agents such as prochlorperazine and promethazine are seldom effective, and have the associated risk of extrapyramidal symptoms. Sedation and anxiolysis with agents such as lorazepam is important, as sleep decreases vomiting frequency. Proton pump inhibitors or H2 blockers should also be considered for children with prolonged or frequent episodes of vomiting. Numerous medications are used for prophylaxis, although the quality of evidence to support these agents is limited to anecdotal reports and poorly controlled clinical trials. Antimigraine medications may be effective in those with a family history of migraines. Anticonvulsants, tricyclic antidepressants (TCA'S), carnitine and erythromycin have been reported as effective in limited trials. It is recommended to use a sequential trial of agents starting with the safest agents first (pizotifen, cyproheptadine, propranolol, carnitine), before progressing to TCA's or anticonvulsants. Further management focuses on controlling episode triggers like anxiety, stress, infection, exercise, trauma, menstruation, or other triggers.